Dizal Pharmaceutical
688192----
Q2 2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Dizal Pharmaceutical(688192) the Revenue is 270.17 M (+38.29%);the EBIT is -121.79 M (+34.04%);the EPS is -0.239 (+41.89%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.27B38.29%
----
----
EBIT
-0.12B34.04%
----
----
EPS
-0.239241.89%
----
----
Upcoming earnings report - Q3 FY2026
Available dateOct 31, 2026
Estimate Revenue--
Estimate EBIT--
Estimate EPS--
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf